Yesterday we talked about PSA, the molecule you hate to need, and certainly one of the most frustrating cancer screening methods in history. We reviewed how trials of population-level screening for asymptomatic patients demonstrated a small mortality benefit, but at the cost of significant overdiagnosis of prostate cancer. And yet the USPSTF is changing their […]